Re: Update on Therapy of Chronic Lymphocytic Leukemia

[Guest guest]

well what are the novel approaches and how does one access this information and

clinical trials.?/?

>

> BlankUpdate on Therapy of Chronic Lymphocytic Leukemia

> 1.. G. Gribben and

> 2.. O'Brien

> + Author Affiliations

>

> 1.. From the Barts Cancer Institute, Barts and The London School of

Medicine, Queen University of London, London, United Kingdom; and The

University of Texas MD Cancer Center, Houston, TX.

> 1.. Corresponding author: G. Gribben, MD, DSc, Barts Cancer Institute,

Barts and the London School of Medicine, Queen University of London,

Charterhouse Square, London EC1M 6BQ United Kingdom; e-mail: j.gribben@...

> Abstract

> There have been tremendous advances in the treatment of chronic lymphocytic

leukemia (CLL) over the past decade, with the goal of therapy no longer being

just to palliate symptoms but now to achieve complete remission, eradicate

minimal residual disease, and improve survival. During this period, there have

also been major advances in identification of molecular factors associated with

increased risk of progression. The clinical utility of these factors is being

explored to determine whether we can identify groups of patients who should be

treated earlier in their disease course and whether we can tailor therapy for

groups of patients with specific molecular markers of disease. First-line

chemoimmunotherapy approaches now offer prolonged survival, and there is a need

to identify patients who are suitable candidates for allogeneic stem-cell

transplantation that uses reduced-intensity conditioning regimens. The vast

majority of CLL patients are either too old or do not have sufficiently

high-risk disease to warrant these approaches, and effective therapies that can

be tolerated by the more frail elderly patients with this disease are urgently

needed. Numerous novel agents are being developed, and their role in the

first-line treatment of frail patients or those who relapse after previous

treatment is being explored in clinical trials.

>

>

>

>

>

[Guest guest]

Hi, I think the most reliable way to consider novel agents is to consult a CLL

expert who can advise based on your unique clinical circumstances ... see for

leads: http://www.lymphomation.org/docs.htm#specialists

For information on novel agents for lymphoma and CLL with links to trials, see

http://www.lymphomation.org/treatment-pipeline.htm and background information

(More) Of these CAL101 and the btk inhibitor have generated interest because of

their favorable saftey profile in early studies.

See also for CLL studies based on treatment status (untreated/previously)

http://www.lymphomation.org/ctlookup.PDF

All the best,

Karl

>

> well what are the novel approaches and how does one access this information

and clinical trials.?/?

>